Month: March 2022

GBT Filed Continuation Application for its Wireless Motion Detection and Imaging Technology

Written by Customer Service on March 29, 2022. Posted in Public Companies.

The Continuation Application Seeks to Cover Wireless Motion Detection and Imaging, Governed by AI SAN DIEGO, March 29, 2022 (GLOBE NEWSWIRE) — GBT Technologies Inc. ( OTC PINK: GTCH ) (“GBT” or the “Company”), filed a continuation application (#17694384) for its wireless motion detection and imaging patent, which has been assigned an internal code name “Apollo”. The non-provisional patent application seeks to protects a radio based, real time motion detection methods and systems. The Company has recently received a notice of allowance with respect to the application. The continuation application aims to broaden the technology’s protection and scope. The patent includes GBT’s AI technology that controls radio waves transmissions/reflections, analyzing the data to construct 2D/3D images of stationary and in-motion objects. The Company...

Identity and Access Management Security Provider BIO-key’s 2021 Revenue Rose 80% to $5.1M, Driven by Demand for Identity-as-a Service Cloud Solutions; Investor Call Today at 10am ET

Written by Customer Service on March 29, 2022. Posted in Earnings Releases And Operating Results.

WALL, N.J., March 29, 2022 (GLOBE NEWSWIRE) — BIO-key International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions featuring Identity-Bound Biometrics (IBB) and large-scale identity solutions, today reported results for its fourth quarter (Q4’21) and year ended December 31, 2021 (FY’21). BIO-key will host a conference call today at 10:00 a.m. ET (details below) to review its results and outlook. BIO-key’s® revenue increased 80% to $5.1M in FY’21, from $2.8M in 2020 (FY’20), driven primarily by deployments of its PortalGuard® IAM solution and the launch of a cloud hosted version, PortalGuard IDaaS (IDentity-as-a-Service), in November 2020. 2021 & Recent Highlights:Increased PortalGuard Penetration of Secondary Educational Institutions – PortalGuard...

Humacyte Reports Fourth Quarter and Year End 2021 Financial Results and Provides Business Update

Written by Customer Service on March 29, 2022. Posted in Earnings Releases And Operating Results.

— Advancing late-stage clinical and preclinical programs of the Human Acellular Vessel™ (HAV™) and other engineered tissues across several indications – — Multiple publications and scientific meeting presentations highlighting clinical and preclinical HAV results – — Conference call and live webcast at 8:00 am ET today – DURHAM, N.C., March 29, 2022 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced financial results for the fourth quarter and year ending December 31, 2021, and highlighted recent corporate accomplishments. “We are proud of the significant progress Humacyte made in 2021, advancing our first-in-class regenerative medicine platform and universally implantable...

Berkshire Grey Reports Fourth Quarter and FY 2021 Results

Written by Customer Service on March 29, 2022. Posted in Earnings Releases And Operating Results.

Exceeds Fourth Quarter and Full Year 2021 Revenue GuidanceEnters 2022 with Backlog of $105 Million BEDFORD, Mass., March 29, 2022 (GLOBE NEWSWIRE) — Berkshire Grey Inc. (Nasdaq: BGRY), a leader in AI-enabled robotic solutions that automate supply chain processes, today announced results for its fourth quarter and year ended 2021. The Company:Delivered revenue of $23.6 million for the fourth quarter of 2021, ahead of expectations and a 556% increase as compared to the fourth quarter of 2020. Entered 2022 with strong backlog of $105 million, positioning the Company well for continued growth. Increased total orders to date to $200 million.“We made substantial commercial progress and achieved important milestones in 2021,” said Tom Wagner, CEO, Berkshire Grey Inc. “We delivered strong revenue growth as Fortune 100 customers continued...

The Lovesac Company Reports Fourth Quarter and Record Fiscal 2022 Financial Results

Written by Customer Service on March 29, 2022. Posted in Earnings Releases And Operating Results.

Net Sales Growth of 51.3% in Fourth Quarter and 55.3% in Fiscal 2022Comparable Sales Growth of 50.0% in Fourth Quarter and 46.9% in Fiscal 2022Net Income Increases to $45.9 million in Fiscal 2022 from $14.7 million in Fiscal 2021Adjusted EBITDA1 Increases to $55.5 million in Fiscal 2022 from $28.3 million in Fiscal 2021 STAMFORD, Conn., March 29, 2022 (GLOBE NEWSWIRE) — The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”), the home furnishing brand best known for its Sactionals, The World’s Most Adaptable Couch™, today announced financial results for the fourth quarter and fiscal year 2022, which ended January 30, 2022. Shawn Nelson, Chief Executive Officer, stated, “Lovesac’s continued strong financial performance in the face of a myriad of macro and industry shifts affirms the power of our unique business model...

SCYNEXIS Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Written by Customer Service on March 29, 2022. Posted in Earnings Releases And Operating Results.

BREXAFEMME® (ibrexafungerp tablets), launched in August 2021, achieved net revenues of $1.1 million in 2021. Fourth quarter 2021 net revenues were $0.6 million.As of the end of 2021, BREXAFEMME was covered by commercial insurance plans representing 81 million or 48% of commercially insured lives. Ibrexafungerp successfully achieved statistically significant superiority over placebo for the primary and key secondary study endpoints in the CANDLE Phase 3 trial for recurrent vulvovaginal candidiasis (rVVC) with a supplemental New Drug Application (sNDA) to be filed in the second quarter of 2022 and potential approval by year end. SCYNEXIS is initiating MARIO, a global Phase 3 study to evaluate ibrexafungerp as an oral step-down treatment for invasive candidiasis (IC) in the hospital setting, with enrollment expected to begin in Q2 2022,...

Better Choice Company Reports Fourth Quarter and Full Year 2021 Financial Results, Provides Update to Halo Elevate Launch and Releases First Quarter 2022 Growth Estimate

Written by Customer Service on March 29, 2022. Posted in Earnings Releases And Operating Results.

NEW YORK, March 29, 2022 (GLOBE NEWSWIRE) — Better Choice Company Inc. (NYSE American: BTTR) (the “Company” or “Better Choice”), a pet health and wellness company, today reported its financial results for the fourth quarter and year ended December 31, 2021. “The fourth quarter of 2021 was a strong quarter for Better Choice. In spite of unprecedented supply chain disruptions felt across the consumer-packaged goods industry, we were able to deliver 18% quarterly net sales growth year-over-year, driven by 227% growth in International sales and 6% growth in E-commerce sales. This quarter, our supply chain and logistics team did a fantastic job navigating supply chain pressures to satisfy our growing customer demand and pivoted when needed with one goal in mind – to keep our product on the shelf for our loyal and growing consumer...

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Written by Customer Service on March 29, 2022. Posted in Earnings Releases And Operating Results.

— Achieved $11.2 Million in Net Revenue in 2021 —— Expanded Coverage for EYSUVIS® to 118 Million Commercial Lives and 7.1 Million Medicare Lives —— KPI-012 Phase 1b Clinical Data Accepted for Presentation at ARVO; Initiation of Phase 2/3 Clinical Trial of KPI-012 expected in 4Q 2022 —— Conference Call and Webcast at 8:00 a.m. ET — ARLINGTON, Mass., March 29, 2022 (GLOBE NEWSWIRE) — Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update. “In recent months, we have made meaningful progress toward our goal of establishing...

Form 8.3 – [Clinigen Group plc – 28 03 2022] – (CGWL)

Written by Customer Service on March 29, 2022. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree CLINIGEN GROUP PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date position held/dealing undertaken: For...

Genetron Health Announces Unaudited Fourth Quarter and Full Year 2021 Financial Results

Written by Customer Service on March 29, 2022. Posted in Earnings Releases And Operating Results.

BEIJING, March 29, 2022 (GLOBE NEWSWIRE) — Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced its unaudited preliminary financial results for the fourth quarter and full year ended December 31, 2021. 2021 and Recent Business HighlightsTherapy Selection:As of December 31, 2021, the Company had 58 hospital partners, of which 30 were IVD hospital partners. Genetron Health is continuing to enhance its in-hospital sales effort.Early Screening:The Company successfully introduced HCCscreen™ in China as an LDT service for hepatocellular carcinoma (HCC), along with establishing collaborations with channel partners...

Month: March 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals